Abstract
Ovarian cancer is one of the major causes of cancer-related deaths among the female reproductive tract cancers worldwide. The foremost problem with ovarian cancer is in its heterogeneity, different subtypes and drug resistance. Moreover, the different types of ovarian cancer, such as endometrioid, serous, clear cell and mucinous appends to the complexity of this cancer. These tumors contain a small population of cells known as cancer stem cells (CSCs), which have the capacity to self-renew and are highly drug resistant, leading to tumor relapse. CSCs have attained tremendous attention in the last decade and have been shown to be a major target in various cancers including ovarian cancer. Understanding the molecular pathways implicated by ovarian CSCs is crucial to combat the residual disease following chemotherapy and combinational therapies. Several markers, such as CD24, CD44, CD117, CD133 and ALDH1, are found to be highly expressed on the surface of ovarian CSCs and can be used as a target as well as to battle ovarian cancer. This book chapter focuses on CSCs and their associate molecules and molecular pathways involved in the maintenance of ovarian CSCs, specific targets and the novel therapeutic implications of ovarian CSCs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aguilar-Gallardo C, Rutledge EC, Martinez-Arroyo AM, Hidalgo JJ, Domingo S, Simon C (2012) Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev 8(3):994–1010
Bapat SA (2010) Human ovarian cancer stem cells. Reproduction 140(1):33–41
Chau WK, Ip CK, Mak AS, Lai HC, Wong AS (2012) c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 10. doi:10.1038/onc.2012.290
Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5(2):100–107
Choi JH, Park JT, Davidson B, Morin PJ, Shih I, Wang TL (2008) Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 68(14):5716–5723
De Sousa EM, Vermeulen L, Richel D, Medema JP (2011) Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 17(4):647–653
Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Butzow R, Coukos G, Zhang L (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5(4):e10277
Dyall S, Gayther SA, Dafou D (2010) Cancer stem cells and epithelial ovarian cancer. J Oncol 2010:105269
Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G (2009) CD133 antigen expression in ovarian cancer. BMC Cancer 9:221
Gamallo C, Palacios J, Moreno G, de Calvo MJ, Suarez A, Armas A (1999) beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155(2):527–536
Gao MQ, Choi YP, Kang S, Youn JH, Cho NH (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29(18):2672–2680
Hadden MK (2013) Hedgehog pathway inhibitors: a patent review (2009 – present). Expert Opin Ther Pat 23(3):345–361
Hopfer O, Zwahlen D, Fey MF, Aebi S (2005) The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 93(6):709–718
Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY, An HJ (2010) Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci 101(9):1977–1983
Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM (2012) High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109(10):3921–3926
Koh J, Lee SB, Park H, Lee HJ, Cho NH, Kim J (2012) Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells. Biochem Biophys Res Commun 427(2):373–378
Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30(19):2307–2313
Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186–3199
Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH (2003) beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 88(3):363–368
Lin TL, Matsui W (2012) Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther 5:47–58
Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL, Darling JL, Wang W (2012) Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 107(9):1488–1497
LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD (2011) Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17(8):2502–2511
Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G (2008) Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 113(4):723–732
McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J Jr, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM (2012) Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 109(43):E2939–E2948
Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18(4):260–267
Platt VM, Szoka FC Jr (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5(4):474–486
Ponnusamy MP, Batra SK (2008) Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 1(1):4
Raspollini MR, Amunni G, Villanucci A, Baroni G, Taddei A, Taddei GL (2004) c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol 15(4):594–597
Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434(7035):843–850
Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J (2010) Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol 23(1):113–122
Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337(6095):730–735
Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC (2008) Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 26(20):3418–3425
Shan J, Shi DL, Wang J, Zheng J (2005) Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44(47):15495–15503
Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, Moore PA, Ruben SM, Carter PJ (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99(1):100–109
Su D, Deng H, Zhao X, Zhang X, Chen L, Chen X, Li Z, Bai Y, Wang Y, Zhong Q, Yi T, Qian Z, Wei Y (2009) Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 11(5):642–652
Szkandera J, Kiesslich T, Haybaeck J, Gerger A, Pichler M (2013) Hedgehog signaling pathway in ovarian cancer. Int J Mol Sci 14(1):1179–1196
Taipale J, Beachy PA (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature 411(6835):349–354
Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ (2012) Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30(19):2348–2353
Yan M (2011) Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell 3:17
Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68(11):4311–4320
Acknowledgements
 The authors on this book chapter were supported by the grant from the Elsa U Pardee Foundation (2013).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Vaz, A.P., Seshacharyulu, P., Batra, S.K., Ponnusamy, M.P. (2014). Identification of Ovarian Cancer Stem Cells: Molecular Pathways. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 11. Stem Cells and Cancer Stem Cells, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7329-5_15
Download citation
DOI: https://doi.org/10.1007/978-94-007-7329-5_15
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7328-8
Online ISBN: 978-94-007-7329-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)